Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Testicular cancer incidence predictions in Europe 2010–2035: A rising burden despite population ageing

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Tibolone and risk of gynecological hormone sensitive cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Does HPV status influence survival after vulvar cancer?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prognostic utility of serum YKL-40 in patients with cervical cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Elevated plasma YKL-40 and risk of infectious disease: a prospective study of 94665 individuals from the general population

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Triage May Improve Selection to Colonoscopy and Reduce the Number of Unnecessary Colonoscopies

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
YKL-40 is a glycoprotein secreted by macrophages, neutrophils and malignant tumor cells. Elevated serum levels of YKL-40 are associated with poor prognosis in several malignancies. In this study, we examined the prognostic value of serum YKL-40 before treatment and during follow-up in patients with squamous cell carcinoma of the head and neck (HNSCC). YKL-40 was determined by ELISA retrospectively in serum from 173 patients with primary HNSCC before treatment and up to 2 years after treatment. Median follow-up time was 7.9 years. YKL-40 protein expression in tumor biopsies was assessed by immunohistochemistry in 50 patients. Pretreatment serum YKL-40 was elevated in 53%. Patients with high serum YKL-40 had shorter survival than patients with normal serum YKL-40 (33 vs. 84 months; p = 0.008). Multivariate Cox analysis including pretreatment serum YKL-40, age, sex, primary tumor site, TNM classification and treatment demonstrated that TNM classification (HR = 2.61, p = 0.02) and serum YKL-40 (log-transformed continuous variable: HR = 1.55, p
Original languageEnglish
JournalInternational journal of cancer. Journal international du cancer
Volume122
Issue number4
Pages (from-to)857-63
Number of pages7
ISSN0020-7136
DOIs
Publication statusPublished - 15 Feb 2008

    Research areas

  • Adipokines, Adult, Aged, Aged, 80 and over, Autoantigens, Carcinoma, Squamous Cell, Case-Control Studies, Female, Glycoproteins, Head and Neck Neoplasms, Humans, Lectins, Male, Middle Aged, Prognosis, Prospective Studies, Survival Rate, Tumor Markers, Biological

ID: 42998747